Literature DB >> 19519430

Regulatory T cells: major players in the tumor microenvironment.

Marc Beyer1, Joachim L Schultze.   

Abstract

Over the last years a number of reports have described elevated numbers of regulatory T (Treg) cells inside of tumors, in close proximity of the tumor, draining lymph nodes and also in peripheral blood of patients with solid tumors and hematologic malignancies. There is increasing evidence that Treg cells can migrate into tumors and suppress effective anti-tumor responses in the tumor microenvironment, thus contributing to the prosperity and growth of human tumors. In addition, several mechanisms have been described how conversion of conventional CD4(+) T cells into Treg cells can occur in the context of human tumors, yet little is known about the molecular and cellular features responsible for the increase and maintenance of elevated levels of Treg cells in cancer. Recent studies now have elucidated how Treg cells mediate regulatory activity in the tumor microenvironment and enhanced our understanding of the underlying molecular mechanisms. Targeting Treg cells therefore provides an attractive therapeutic strategy to potentially influence the suppressed immune response in tumor patients thereby altering and supporting anti-tumor therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19519430     DOI: 10.2174/138161209788453211

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  23 in total

Review 1.  Hyaluronan in immune dysregulation and autoimmune diseases.

Authors:  Nadine Nagy; Hedwich F Kuipers; Payton L Marshall; Esther Wang; Gernot Kaber; Paul L Bollyky
Journal:  Matrix Biol       Date:  2018-04-04       Impact factor: 11.583

Review 2.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 3.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

Review 4.  Challenges and future perspectives of T cell immunotherapy in cancer.

Authors:  Maria Teresa P de Aquino; Anshu Malhotra; Manoj K Mishra; Anil Shanker
Journal:  Immunol Lett       Date:  2015-06-19       Impact factor: 3.685

Review 5.  Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings.

Authors:  Sachin Kumar Deshmukh; Sanjeev K Srivastava; Nikhil Tyagi; Aamir Ahmad; Ajay P Singh; Ahmed A L Ghadhban; Donna L Dyess; James E Carter; Kari Dugger; Seema Singh
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.944

6.  Co-graft of allogeneic immune regulatory neural stem cells (NPC) and pancreatic islets mediates tolerance, while inducing NPC-derived tumors in mice.

Authors:  Raffaella Melzi; Barbara Antonioli; Alessia Mercalli; Manuela Battaglia; Andrea Valle; Stefano Pluchino; Rossella Galli; Valeria Sordi; Emanuele Bosi; Gianvito Martino; Ezio Bonifacio; Claudio Doglioni; Lorenzo Piemonti
Journal:  PLoS One       Date:  2010-04-27       Impact factor: 3.240

7.  Prognostic value of regulatory T cells in newly diagnosed chronic myeloid leukemia patients.

Authors:  Asmaa M Zahran; Hosny Badrawy; Abeer Ibrahim
Journal:  Int J Clin Oncol       Date:  2013-09-26       Impact factor: 3.402

8.  Interleukin-2 treatment of tumor patients can expand regulatory T cells.

Authors:  Marc Beyer
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

Review 9.  Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis.

Authors:  Hong-Qiang Zhao; Wei-Min Li; Zhong-Qiou Lu; Yong-Ming Yao
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

Review 10.  Gold nanoparticle mediated cancer immunotherapy.

Authors:  Joao Paulo Mattos Almeida; Elizabeth Raquel Figueroa; Rebekah Anna Drezek
Journal:  Nanomedicine       Date:  2013-10-05       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.